Cardiolipin Antibody (IgG) - High-Sensitivity
This test measures the presence of antibodies against cardiolipin, a phospholipid found in cell membranes. These antibodies may be linked to certain autoimmune conditions.
This test helps assess potential autoimmune or inflammatory conditions, including lupus or other connective tissue disorders.
Key facts at a glance
- LOINC
- 42729-4
- Short code
- CARDIGA
- Synonyms
- Cardiolipin IgA B2GP1 dep MoM Ser
- Category
- chemistry
- Sample
- serum
- Container
- Serum separator tube (SST) - red-top or gold-top tube
- Units
- N/A
- Ref low
- 20
- Ref high
- 39
- Critical range
- — – 80 N/A
- Fasting
- false
- Population
- adult
- Sex
- all
- Age range
- 18–99 years
- Method
- Enzyme-linked immunosorbent assay (ELISA) detecting IgA antibodies against cardiolipin complexed with beta-2 glycoprotein 1
- CPT
- 86147
- SNOMED
- 12182000
- Specimen volume
- 1.0 mL serum (minimum 0.5 mL)
- Stability
- Room temperature: 8 hours; Refrigerated (2-8°C): 7 days; Frozen (-20°C or below): 30 days. Avoid repeated freeze-thaw cycles.
- Hemolysis max
- 100
- Lipemia max
- 100
- Icterus max
- 50
- TAT
- 24–72 hours
- Order
- routine
Why This Test Might Be Ordered
Your healthcare provider may recommend this test if you have symptoms or a history suggestive of autoimmune diseases, such as joint pain, fatigue, or unexplained rashes. It can also be part of a broader evaluation for conditions like lupus or antiphospholipid syndrome.
What to Expect Before the Test
No special preparation is needed. You’ll provide a blood sample, typically drawn from a vein in your arm. If you’re on blood thinners, inform your provider before the test.
What the Results Mean
Positive results indicate the presence of cardiolipin antibodies, which may signal an autoimmune response. However, results alone don’t diagnose a condition—your provider will consider them alongside other factors, including symptoms and lab results.
Common Conditions Linked to Positive Results
Elevated levels of these antibodies are often associated with autoimmune disorders like systemic lupus erythematosus (SLE), antiphospholipid syndrome, or other connective tissue diseases. They may also appear in people with no symptoms.
Reference range
Negative: <20 MPL-U/mL (Multiple of the Median); Equivocal: 20-39 MPL-U/mL; Positive: ≥40 MPL-U/mL. Reference ranges expressed as multiples of the median (MoM) of a healthy reference population.N/A
No fasting required. Patient should be informed that this test should be repeated after at least 12 weeks to confirm persistent positivity, as recommended by international antiphospholipid syndrome classification criteria.
Clinical interpretation
How abnormal results are interpreted and what conditions they suggest.
This test plays a key role in diagnosing or monitoring autoimmune conditions where phospholipid antibodies are suspected. While not definitive, it helps guide further testing or treatment decisions. False positives can occur, so results should be interpreted with clinical context.
Short name
IgG Cardiolipin Antibody (High-Sens)
Frequently asked questions
Will this test show if I have lupus?
What does a positive result mean for my health?
Can I stop taking medications before this test?
Sources
- 1
- 2Lab Tests OnlineSource
- 3
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 15, 2026. · Read our editorial policy